Ibalizumab
(Anti-human CD4 mAb, human IgG4-Kappa; TMB-355)
Catalog No.: PC-Ab1096Not For Human Use, Lab Use Only.
Ibalizumab (TMB-355) is a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4 T cell receptors. Ibalizumab specifically leads to conformational changes of the CD4 T cell receptor-gp120 complex thus preventing HIV fusion and entry. Ibalizumab is classified as an entry inhibitor. However, its action mechanism differs from previously known HIV entry inhibitors such as enfuvirtide (a HIV fusion inhibitor) and maraviroc
Ibalizumab (TMB-355) is a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4 T cell receptors. Ibalizumab specifically leads to conformational changes of the CD4 T cell receptor-gp120 complex thus preventing HIV fusion and entry. Ibalizumab is classified as an entry inhibitor. However, its action mechanism differs from previously known HIV entry inhibitors such as enfuvirtide (a HIV fusion inhibitor) and maraviroc (a CCR5 coreceptor antagonist).
Physicochemical Properties
M.Wt
Formula
Human IgG4-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
